Abstract Purpose Irinotecan hydrochloride (CPT-11) is a potent topoisomerase I inhibitor
and is established and used widely as an antitumor agent. However, it sometimes causes …

Purpose: Clinically, diarrhea is the major dose-limiting toxicity of irinotecan hydrochloride
(CPT-11). Using a rat model, we attempted to decrease the incidence of delayed-onset …

Diarrhoea is the major dose-limiting toxicity of irinotecan hydrochloride (CPT-11) in the
clinical setting. This study was designed to evaluate the effects of different pharmacological …

CPT11 isa a topoisomerase I inhibitor with substantial anti tumor activity. Preclinical data
suggest that prolonged exposure has better efficacy and possibly less toxicity. A dose …

Abstract Irinotecan (CPT-11) is a new drug active in colorectal cancer. A comparison was
made of the efficacy and pharmacokinetics of CPT-11 after ip versus iv administration to …

Irinotecan (CPT-11) and its main metabolite SN-38 are potent anticancer derivatives of
camptothecin (CPT), with active lactone and inactive carboxylate forms coexisting. A simple …

Purpose. To investigate the excretion of irinotecan hydrochloride (CPT-11) and its active
metabolite, SN-38, into the gastrointestinal lumen via the biliary and/or intestinal membrane …

Abstract Irinotecan (CPT-11) is a novel water-soluble, semisynthetic derivative of
camptothecin, with inhibitory effects on mammalian DNA topoisomerase I, high cytotoxic …

Introduction: The main clinical adverse effect of irinotecan (CPT-11) therapy is diarrhoea.
Using a rat model, we attempted to study the effects of activated charcoal on the prevention …

Abstract Irinotecan (CPT-11) is a derivative of the chemotherapeutic agent camptothecin.
CPT-11 inhibits the nuclear enzyme topoisomerase I. It has demonstrated a broad spectrum …